NC-LENOVO
15.2.2024 15:01:34 CET | Business Wire | Press release
Today, Lenovo™ announced a strategic partnership with Anaconda® Inc., the leading provider of the world’s most popular artificial intelligence (AI), machine learning (ML) and data science platform, to empower Lenovo’s high performance data science workstations. The partnership will couple Lenovo’s trusted ThinkStation™ and ThinkPad™ workstation product portfolio heritage and leadership with Anaconda’s enterprise strengths for open-source leadership, security, and reliability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240215334255/en/
Lenovo and Anaconda Announce Agreement to Accelerate AI Development and Deployment (Photo: Business Wire)
The rapidly evolving world of artificial intelligence, deep learning and generative AI is opening up new opportunities for businesses and data scientists. Much of the AI innovation taking place today is driven by open-source software and cloud-based solutions, with Python being a leading software language for AI applications. However, the data security risks associated with utilizing open-source software at an enterprise level, privacy concerns and often prohibitive cost of cloud-based AI solutions, is causing many organizations to rethink their approach to investment in AI development. With Intel®-powered Lenovo workstations architected with the latest generations of professional NVIDIA® GPUs built for large-language model fine-tuning, and the Anaconda Navigator’s ability to enable businesses to leverage open-source and AI with enhanced security, scale, and governance mechanisms in place, the partnership allows data scientists to create and deploy AI solutions with first class hardware and enterprise-grade AI software support within a more manageable investment framework.
Optimized for Intel platforms, Lenovo’s new generation of data science workstations deliver remarkable AI performance and is one of the world’s most powerful and scalable AI workstation portfolios. Planning for AI projects requires clear and thoughtful pathways to allocate the right hardware, software and skillsets to manage each stage of AI development. Lenovo workstations complement cloud-based AI solutions by acting as a bridge between local and cloud resources and aid data scientist flexibility and productivity. Lenovo’s full workstation portfolio includes highly configurable systems designed for nearly every AI workflow, industry or vertical, size and price point – all architected to drive the future of AI forward in an agile and cost-efficient way. From single CPU and GPU mobile workstations that are ideal for data input, collection and preparation, to the most powerful dual CPU and four GPU configurations for advanced AI workflows, Lenovo workstations with Anaconda Navigator offer protected “sandbox” environments to tackle the most complex AI solution development and deployment.
“With Lenovo’s trusted workstation leadership and Anaconda’s trusted leadership in open-source software support and reliability, the partnership is a perfect match,” said Rob Herman, Vice President and General Manager, Workstation and Client AI Group at Lenovo. “We’re excited to activate this partnership to aid data scientists in pushing forward the capabilities of AI with our premium workstations portfolio and Anaconda’s stellar open-source packages and repositories.”
Anaconda Navigator is available for download to use on current and future generation Lenovo Workstations.
“As artificial intelligence and machine learning models grow increasingly complex, high-performance workstations are imperative to empower data scientists with advanced capabilities,” said Chandler Vaughn, Chief Product Officer at Anaconda. “Lenovo's leadership in supplying optimized workstations, featuring robust GPUs, memory, and storage, positions them as an ideal collaborator for Anaconda and our Navigator desktop product. By jointly providing resilient hardware and trusted software tools, Lenovo and Anaconda present data scientists, AI developers, and AI engineers an unrivaled platform to freely explore emerging techniques in AI/ML. This symbiotic relationship enables organizations to push boundaries and accelerate innovations in artificial intelligence without technological constraints.”
For more information about Lenovo’s workstation portfolio, visit www.lenovo.com/workstations.
About Lenovo
Lenovo is a US$62 billion revenue global technology powerhouse, ranked #217 in the Fortune Global 500, employing 77,000 people around the world, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company by further expanding into growth areas that fuel the advancement of ‘New IT’ technologies (client, edge, cloud, network, and intelligence) including server, storage, mobile, software, solutions, and services. This transformation together with Lenovo’s world-changing innovation is building a more inclusive, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992)(ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.
About Anaconda
With more than 45 million users, Anaconda is the most popular operating system for AI providing access to the foundational open-source Python packages used in modern AI, data science and machine learning through a seamless platform. We pioneered the use of Python for data science, championed its vibrant community, and continue to steward open-source projects that make tomorrow’s innovations possible. Our enterprise-grade solutions enable corporate, research, and academic institutions around the world to harness the power of open-source for competitive advantage, groundbreaking research, and a better world. To learn more visit anaconda.com or connect on Twitter or LinkedIn.
LENOVO, THINKSTATION and THINKPAD are trademarks of Lenovo. Anaconda is a registered trademark owned by Anaconda, Inc. Intel is a trademark of Intel Corporation or its subsidiaries in the U.S. and/or other countries. NVIDIA is a trademark of NVIDIA Corporation. Inc. All other trademarks are the property of their respective owners. ©2024 Lenovo Group Limited.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215334255/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release
Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release
ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release
Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom